Plan Japan in early
Include Japanese or East Asian arms in your pivotal multi-regional trial. Cheaper and faster than a standalone bridging study bolted on later.
Best case: no separate bridgeJapan is one of the largest pharmaceutical markets in the world, with a super-ageing population and deep unmet demand for innovative medicines. It is also one of the most particular: a foreign company cannot hold its own approval, foreign trial data is welcome but rarely sufficient on its own, and the state sets your price and then trims it, year after year. For German pharma the prize is real — if you plan for how Japan actually works.
Japan regulates medicines through the MHLW, which grants the marketing authorisation, and the PMDA, which runs the scientific review. A foreign manufacturer cannot hold a Japanese approval directly: you appoint either a Japan-based MAH that owns the registration, or a DMAH (Designated MAH) that represents you while you keep ownership — a DMAH is easier to change and usually the better first move. Japan accepts foreign data under ICH E5, but ethnic-factor concerns mean a bridging study or Japanese participation in a global trial is often still needed — though a December 2023 guideline eased the old mandatory Japanese Phase I. Once approved, the price is not yours to set: the drug is listed at an NHI price decided by the MHLW, and since 2021 that price is revised — usually downward — every year. Reforms since FY2024 add a new-drug premium to reverse the “drug loss” of companies skipping Japan, so the window for innovators is arguably opening even as the pricing grind continues.
Japan rewards companies that treat it as its own project, and punishes those that treat it as “another developed market.” The rules are stable and knowable — and unlike anywhere in Europe.
The case for Japan is strong: a huge, wealthy, ageing population; sophisticated clinicians; and a health system that will pay for genuine innovation. For a German company with a differentiated medicine, it is one of the most valuable single markets on earth.
The catch is that almost every mechanism differs from what you know. Who may hold your approval, what evidence the regulator wants, and how your price is set and maintained all follow Japanese logic, not European. None of it is hostile — but none of it is automatic, and each has caught out German entrants who assumed their EU dossier and EU pricing instincts would travel.
Japan is not a hard market. It is a specific one — and specificity is what unprepared entrants underestimate.
Japan's path is orderly and evidence-heavy, and two of its steps — who holds your approval, and what data Japan needs — must be settled before you file, not discovered during review.
Decide the indication, the comparator context, and — critically — whether Japanese or bridging data will be required. This shapes everything downstream.
A Japan-based Marketing Authorisation Holder, or a Designated MAH (DMAH) that represents you while you retain ownership. Nothing can be filed without one.Not waivable
Foreign data under ICH E5, plus — where needed — a bridging study or Japanese arms in a multi-regional trial (ICH E17). Confirm the requirement early.Ethnic-factor review
The PMDA conducts the technical assessment, including consultations. Dossiers and interaction are in Japanese. Expedited routes exist for priority and orphan products.
The Ministry grants the approval on the PMDA's assessment. Ongoing MAH duties — safety, supply and, since the 2025 PMD Act amendments, a designated supply manager — begin here.
The drug is listed at a state-set NHI reimbursement price. Only now do you reach the market — and the annual price revision begins to apply.
This is Japan's version of the question we ask on every corridor — who legally holds your product — and it has a Japan-specific twist worth getting right.
A foreign manufacturer cannot hold a Japanese marketing approval itself. You have two structures. With an MAH (Marketing Authorisation Holder), a Japanese entity owns and controls the registration and the approval. With a DMAH (Designated Marketing Authorisation Holder), the foreign manufacturer keeps ownership and control of the registration, and the DMAH acts as the accountable representative in Japan.
The distinction is not academic. If your holder relationship ever has to change — a partner switch, a restructuring, a dispute — changing a DMAH is materially easier than changing an MAH, because you never handed over ownership in the first place.
Letting a Japanese partner become your MAH — owning the approval — is convenient at entry and costly to reverse. If the commercial relationship sours, the legal permission to sell your drug in Japan sits with them, and prying it back is slow and expensive.
For most German companies entering deliberately, a DMAH structure — you own the approval, a designated representative carries the Japanese responsibility — keeps control where it belongs and keeps your options open. It is the same principle we set out for the Brazilian Registration Holder and the Chinese legal agent: separate ownership from representation.
The old fear — that Japan demands a full local trial programme — is out of date. The new reality is more nuanced, and more manageable, but not free.
Japan is an ICH member and, under ICH E5, accepts foreign clinical data. But because of long-standing concerns about ethnic differences in how medicines behave, that data is often not sufficient on its own for a novel drug. The two common answers are a bridging study — typically a pharmacokinetic study in Japanese subjects showing similarity to your foreign data — or building Japanese sites into a multi-regional clinical trial from the outset, which the PMDA encourages under ICH E17.
The direction of travel is easing. A December 2023 MHLW guideline generally waives the previously near-mandatory Japanese Phase I study where foreign data already show comparable safety. For a German company that plans early, the smartest move is usually to design Japan into a global trial rather than bolt a bridging study on afterwards.
Include Japanese or East Asian arms in your pivotal multi-regional trial. Cheaper and faster than a standalone bridging study bolted on later.
Best case: no separate bridgeWhere global data already exist, a Japanese PK/PD bridging study can extrapolate them — the fallback when Japan wasn't designed in from the start.
Fallback: adds time and costHere is where European pricing instincts fail hardest. In Japan you do not set your price and defend it — the state lists it, and then reduces it on a schedule.
Nearly everyone in Japan is covered by national health insurance. When your drug is approved, it is listed at an NHI reimbursement price set by the MHLW — on advice from the Chuikyo council — using formulas that reference comparable products and, for some imported drugs, average foreign prices. That listing is the market: it is how you are paid.
The hard part comes after listing. Japan now revises NHI prices every year — the eighth consecutive annual revision applied from FY2025 — and the pressure is generally downward, even for patented products whose market price drifts below the official one. A Price Maintenance Premium can let genuinely innovative, on-patent drugs defer those cuts, but you must qualify and stay qualified.
A German team that models Japan on its launch price will overstate the opportunity. The realistic model is a price that starts at the NHI listing and steps down over the product's life unless the maintenance premium protects it. Build the annual revision into the business case from day one.
It is the Japanese form of the thesis under all our work: being approved and listed is not the same as being paid what you expected. We set it out in authorized isn't paid.
Against that pricing pressure sits a genuinely encouraging trend: Japan is actively trying to make itself easier for foreign innovators, because it noticed them staying away.
Years of unpredictable price cuts contributed to “drug loss” — innovative medicines, often from smaller foreign companies, simply not being launched in Japan. The government has responded. The FY2024 reform introduced a new premium of roughly 5–10% to reward the early introduction of innovative drugs, simplified the price-maintenance-premium system, and added price adjustments referencing average foreign prices. The 2025 PMD Act amendments expand conditional approval and R&D support.
Start with a fixed, written deliverable for the Japan corridor, then plan execution in a working session — above all the holder structure and your data and pricing strategy, which are expensive to get wrong.
A one-off written roadmap for Japan — the route, the holder decision and an honest read on data and NHI pricing before you commit.
A focused session to structure the holder relationship, plan the evidence strategy, and weigh Japan against your other markets.